Misplaced Pages

This is an old revision of this page, as edited by Axl (talk | contribs) at 07:29, 10 August 2007 (References updated). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lung cancer
Specialty	Oncology, pulmonology

Lung cancer is the malignant transformation and expansion of lung tissue, and is responsible for 1.3 million deaths worldwide annually. It is the most common cause of cancer-related death in men, and the second most common in women.

The most significant risk factor for developing lung cancer is long-term exposure to inhaled carcinogens, especially tobacco smoke. The occurrence of lung cancer in non-smokers, who account for <10% of cases, appears to be due to a combination of genetic factors. Radon gas and air pollution may also contribute to the development of lung cancer.

Treatment and prognosis depend upon the histological type of cancer, the stage (degree of spread), and the patient's performance status. Possible treatments include surgery, chemotherapy, and radiotherapy. Overall, the five-year survival rate is 14%.

Classification

Types

There are two main types of lung cancer categorized by the size and appearance of the malignant cells seen by a histopathologist under a microscope: non-small cell (80%) and small-cell (roughly 20%) lung cancer. This classification, although based on simple histological criteria, has very important implications for clinical management and prognosis of the disease.

Non-small cell lung cancer (NSCLC)

The non-small cell lung cancers are grouped together because their prognosis and management are roughly identical. There are three main sub-types: squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma. When NSCLC cannot be subtyped, it is assigned SNOMED code 8046/3.

Squamous cell lung carcinoma, accounting for 29% of lung cancers, usually starts near a central bronchus. Cavitation and necrosis within the center of the cancer is a common finding. Well-differentiated squamous cell lung cancers often grow more slowly than other cancer types.

Adenocarcinoma is the most common subtype of NSCLC, accounting for 32% of lung cancers. It usually originates in peripheral lung tissue. Most cases of adenocarcinoma are associated with smoking. However, among people who have never smoked ("never-smokers"), adenocarcinoma is the most common form of lung cancer. A subtype of adenocarcinoma, the bronchioloalveolar carcinoma, is more common in female never-smokers, and may have different responses to treatment.

Large cell carcinoma is a fast-growing form, accounting for 9% of lung cancers, that grows near the surface of the lung. It is often poorly differentiated and tends to metastasize early.

Small cell lung cancer (SCLC)

Small cell lung cancer (SCLC, also called "oat cell carcinoma") is the less common form of lung cancer. It tends to start in the larger breathing tubes and grows rapidly becoming quite large. The oncogene most commonly involved is L-myc. The "oat" cell contains dense neurosecretory granules which give this an endocrine/paraneoplastic syndrome association. It is initially more sensitive to chemotherapy, but ultimately carries a worse prognosis and is often metastatic at presentation. This type of lung cancer is strongly associated with smoking.

Other types

Rarer forms of lung cancer include carcinoid, adenoid cystic carcinoma (cylindroma) and mucoepidermoid carcinoma.

Metastatic cancers

The lung is a common place for metastasis from tumors in other parts of the body. These cancers, however, are identified by the site of origin, e.g. a breast cancer metastasis to the lung is still known as breast cancer. The adrenal glands, liver, brain, and bone are the most common sites of metastasis from primary lung cancer itself.

Staging

Lung cancer staging is an assessment of the degree of spread of the cancer from its original source. It is an important contributor to the prognosis and potential treatment of lung cancer.

Non-small cell lung cancer is staged from IA ("one A", best prognosis) to IV ("four", worst prognosis).

Small cell lung cancer is classified as limited stage if it is confined to one half of the chest and within the scope of a single radiotherapy field. Otherwise it is extensive stage.

Signs and symptoms

Symptoms that suggest lung cancer include:

• dyspnea (shortness of breath)
• hemoptysis (coughing up blood)
• chronic coughing or change in regular coughing pattern
• wheezing
• chest pain or pain in the abdomen
• cachexia (weight loss), fatigue and loss of appetite
• dysphonia (hoarse voice)
• clubbing of the fingernails (uncommon)
• difficulty swallowing

If the cancer grows in the airway, it may obstruct airflow, causing breathing difficulties. This can lead to accumulation of secretions behind the blockage, predisposing the patient to pneumonia.

Many lung cancers have a rich blood supply. The surface of the cancer may be fragile, leading to bleeding from the cancer into the airway. This blood may subsequently be coughed up.

Depending on the type of tumor, so-called paraneoplastic phenomena may initially attract attention to the disease. In lung cancer, these phenomena may include Lambert-Eaton myasthenic syndrome (muscle weakness due to auto-antibodies), hypercalcemia or SIADH. Tumors in the top (apex) of the lung, known as Pancoast tumors, may invade the local part of the sympathetic nervous system, leading to changed sweating patterns and eye muscle problems (a combination known as Horner's syndrome), as well as muscle weakness in the hands due to invasion of the brachial plexus.

In many patients, the cancer has already spread beyond the original site by the time they have symptoms and seek medical attention. Common sites of metastasis include the bone, such as the spine (causing back pain and occasionally spinal cord compression), the liver and the brain.

About 10% of people with lung cancer do not have symptoms of it at the time of diagnosis; these cancers are usually found on routine chest x-rays.

Unfortunately, many of the symptoms of lung cancer (bone pain, fever, weight loss ) are nonspecific and in the elderly may be attributed to comorbid illness.

Causes

The main causes of lung cancer (and cancer in general) include carcinogens (such as those in tobacco smoke), ionizing radiation, and viral infection. This exposure causes cumulative changes to the DNA in the tissue lining the bronchi of the lungs (the bronchial epithelium). As more tissue becomes damaged, eventually a cancer develops.

Smoking

Smoking, particularly of cigarettes, is by far the main contributor to lung cancer. In the United States, smoking is estimated to account for 87% of lung cancer cases (90% in men and 85% in women). Among male smokers, the lifetime risk of developing lung cancer is 17.2%. Among female smokers, the risk is 11.6%. This risk is significantly lower in non-smokers: 1.3% in men and 1.4% in women. Cigarette smoke contains over 60 known carcinogens including radioisotopes from the radon decay sequence, nitrosamine, and benzopyrene. Additionally, nicotine appears to depress the immune response to malignant growths in exposed tissue. The length of time a person continues to smoke as well as the amount smoked increases the person's chances of developing lung cancer. If a person stops smoking, these chances steadily decrease as damage to the lungs is repaired and contaminant particles are gradually vacated. More recent work has shown that, across the developed world, almost 90% of lung cancer deaths are caused by smoking. In addition, there is evidence that lung cancer in never-smokers has a better prognosis than in smokers, and that patients who smoke at the time of diagnosis have shorter survival than those who have quit.

Passive smoking—the inhalation of smoke from another's smoking— is a cause of lung cancer in non-smokers. Studies from the USA (1986, 1992, 1997, 2001, 2003), Europe (1998), the UK (1998), and Australia (1997) have consistently shown a significant increase in relative risk among those exposed to passive smoke.

The Philip Morris tobacco company attempted to delay the release of the 1997 IARC study, to affect the wording of its conclusions, to neutralise its negative results for their business, and to counteract its impact on public and policymakers' opinion.

Recent investigation of sidestream smoke suggests it is more dangerous than direct smoke inhalation.

Asbestos

Asbestos can cause a variety of lung diseases. It increases the risk of developing lung cancer. There is a synergistic effect between tobacco smoking and asbestos in the formation of lung cancer.

Asbestos can also cause cancer of the pleura, called mesothelioma (which is different from lung cancer).

Radon gas

Radon is a colorless and odourless gas generated by the breakdown of radioactive radium, which in turn is the decay product of uranium, found in the earth's crust. The radiation decay products ionize genetic material, causing mutations that sometimes turn cancerous. Radon exposure is the second major cause of lung cancer after smoking.

Radon gas levels vary by locality and the composition of the underlying soil and rocks. For example, in areas such as Cornwall in the UK (which has granite as substrata), radon gas is a major problem, and buildings have to be force-ventilated with fans to lower radon gas concentrations. The United States Environmental Protection Agency (EPA) estimates that one in 15 homes in the USA has radon levels above the recommended guideline of 4 picoCuries per liter (pCi/L). Iowa has the highest average radon concentration in the United States; studies performed there have demonstrated a 50% increased lung cancer risk with prolonged radon exposure above the EPA's action level of 4 pCi/L.

Viruses

Viruses are known to cause lung cancer in animals and recent evidence suggests similar potential in humans. Implicated viruses include human papillomavirus, JC virus, simian virus 40 (SV40), BK virus and cytomegalovirus.

Pathophysiology

Similar to many other cancers, lung cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes.

Oncogenes are genes that are believed make people more susceptible to cancer. Proto-oncogenes are believed to turn into oncogenes when exposed to particular carcinogens. Mutations in the K-ras proto-oncogene are responsible for 20-30% of non-small cell lung cancers.

Chromosomal damage can lead to loss of heterozygosity. This can cause inactivation of tumor suppressor genes. Damage to chromosomes 3p, 5q, 13q and 17p are particularly common in small cell lung carcinoma. The TP53 tumor suppressor gene, located on chromosome 17p, is often affected.

Several genetic polymorphisms are associated with lung cancer. These include polymorphisms in interleukin-1, cytochrome P450 and DNA repair molecules such as XRCC1. People with these polymorphisms are more likely to develop lung cancer after exposure to carcinogens.

Diagnosis

Performing a chest x-ray is the first step if a patient reports symptoms that may be suggestive of lung cancer. This may reveal an obvious mass, widening of the mediastinum (suggestive of spread to lymph nodes there), atelectasis (collapse), consolidation (infection) and pleural effusion. If there are no X-ray findings but the suspicion is high (e.g. a heavy smoker with blood-stained sputum), bronchoscopy and/or a CT scan may provide the necessary information. In any case, bronchoscopy or CT-guided biopsy is often necessary to identify the tumor type.

The differential diagnosis for patients who present with abnormalities on chest x-ray includes lung cancer, as well as other nonmalignant diseases. These include infectious causes such as tuberculosis or pneumonia, or inflammatory conditions such as sarcoidosis. These diseases can result in mediastinal lymphadenopathy or lung nodules, and sometimes mimic lung cancers.

Prevention

Primary prevention

Prevention is the most cost-effective means of fighting lung cancer on the national and global scales. While in most countries industrial and domestic carcinogens have been identified and banned, tobacco smoking is still widespread. Eliminating tobacco smoking is a primary goal in the prevention of lung cancer, and smoking cessation is an important preventative tool in this process.

Policy interventions to decrease passive smoking (e.g. in restaurants and workplaces) have become more common in various Western countries, with California taking a lead in banning smoking in public establishments in 1998, Ireland playing a similar role in Europe in 2004, followed by Italy and Norway in 2005 and Scotland as well as several others in 2006, and England in 2007. New Zealand has also recently banned smoking in public places.

Only the Asian state of Bhutan has a complete smoking ban (since 2005). In many countries pressure groups are campaigning for similar bans. Arguments cited against such bans are criminalisation of smoking, increased risk of smuggling and the risk that such a ban cannot be enforced.

Screening

Screening refers to the use of medical tests to detect disease in asymptomatic people. Possible screening tests for lung cancer include chest x-ray or computed tomography (CT) of the chest.

So far, screening programs for lung cancer have not demonstrated any clear benefit. However randomized controlled trials are underway in this area to see if decreased long-term mortality can be directly observed from CT screening.

Treatment

Treatment for lung cancer depends on the cancer's specific cell type, how far it has spread, and the patient's performance status. Common treatments include surgery, chemotherapy, and radiation therapy.

Surgery

If investigations confirm lung cancer, CT scan and often positron emission tomography (PET) are used to determine whether the disease is localised and amenable to surgery or whether it has spread to the point where it cannot be cured surgically.

Blood tests and spirometry (lung function testing) are also necessary to assess whether the patient is well enough to be operated on. If spirometry reveals a very poor respiratory reserve, as may occur in chronic smokers, surgery may be contraindicated.

Surgery itself has an overall operative death rate of 5%, depending on the patient's lung function and other risk factors. Surgery is usually only an option in non-small cell lung cancer limited to one lung, up to stage IIIA. This is assessed with medical imaging (computed tomography, positron emission tomography). A sufficient pre-operative respiratory reserve must be present to allow adequate lung function after the tissue is removed.

Procedures include wedge excision (removal of part of a lobe), lobectomy (one lobe), bilobectomy (two lobes) or pneumonectomy (whole lung). In patients with adequate respiratory reserve, lobectomy is the preferred option, as this minimizes the chance of local recurrence. If the patient does not have enough functional lung for this, wedge excision may be performed. Radioactive iodine brachytherapy at the margins of wedge excision may reduce recurrence to that of lobectomy.

Chemotherapy

Small cell lung cancer is treated primarily with chemotherapy, as surgery has no demonstrable influence on survival. Primary chemotherapy is also given in metastatic non-small cell lung cancer.

The combination regimen depends on the tumor type. Non-small cell lung cancer is often treated with cisplatin or carboplatin, in combination with gemcitabine, paclitaxel, docetaxel, etoposide or vinorelbine. In small cell lung cancer, cisplatin and etoposide are most commonly used. Combinations with carboplatin, gemcitabine, paclitaxel, vinorelbine, topotecan and irinotecan are also used.

Adjuvant chemotherapy

Adjuvant chemotherapy refers to the use of chemotherapy after surgery to improve the outcome. During surgery, samples are taken from the lymph nodes. If these samples contain cancer, then the patient has stage II or III disease. In this situation, adjuvant chemotherapy may improve survival by up to 15%.

Standard practice is to offer platinum-based chemotherapy (e.g. cisplatin and vinorelbine).

Adjuvant chemotherapy for patients with stage IB cancer is controversial as clinical trials have not clearly demonstrated a survival benefit.

Trials of preoperative chemotherapy (neoadjuvant chemotherapy) in resectable non-small cell lung cancer have been inconclusive.

Radiotherapy

Radiotherapy is often given together with chemotherapy, and may be used with curative intent in patients with non-small cell lung cancer who are not eligible for surgery. For small cell lung cancer cases that are potentially curable, in addition to chemotherapy, chest radiation is often recommended.

For both non-small cell lung cancer and small cell lung cancer patients, smaller doses of radiation to the chest may be used for symptom control (palliative radiotherapy). Unlike other treatments, it is possible to deliver palliative radiotherapy without confirming the histological diagnosis of lung cancer.

Patients with small cell lung carcinoma are usually given prophylactic cranial irradiation (PCI). This is a type of radiotherapy to the brain, used to reduce the risk of metastasis.

Interventional radiology

Radiofrequency ablation is increasing in popularity for this condition as it is nontoxic and causes very little pain. It seems especially effective when combined with chemotherapy as it catches the cells deeper inside a tumor—the ones difficult to get with chemotherapy due to reduced blood supply to the center of the tumor. It is done by inserting a small heat probe into the tumor to kill the tumor cells.

Targeted therapy

In recent years, various molecular targeted therapies have been developed for the treatment of advanced lung cancer. Gefitinib (Iressa) is one such drug, which targets the tyrosine kinase domain of the epidermal growth factor receptor (EGF-R) which is expressed in many cases of non-small cell lung cancer. However despite an exciting start it was not shown to increase survival, although females, Asians, non-smokers and those with the bronchioloalveolar carcinoma cell type appear to be deriving most benefit from gefitinib.

Erlotinib (Tarceva), another tyrosine kinase inhibitor, has been shown to increase survival in lung cancer patients and has recently been approved by the FDA for second-line treatment of advanced non-small cell lung cancer. Similar to gefitinib, it appeared to work best in females, Asians, non-smokers and those with the bronchioloalveolar carcinoma cell type.

Emerging treatments

A number of targeted agents are at the early stages of clinical research, such as cyclo-oxygenase-2 inhibitors, the apoptosis promoter exisulind, proteasome inhibitors, bexarotene and vaccines.

The treatment of lung cancer continues to evolve. Advances in cytotoxic drugs, pharmacogenetics and targeted drug design show promise.

Prognosis

Prognosis depends on the cell type (histology), stage (degree of spread), and the patient's performance status. Overall, the 5-year survival rate is 14%.

Non-small cell lung cancer prognosis

For non-small cell lung cancer, prognosis is poor. Following complete surgical resection of stage IA disease, five-year survival is 67%. With stage IB disease, five-year survival is 57%. The 5-year survival rate of patients with stage IV NSCLC is about 1%.

Small cell lung cancer prognosis

For small cell lung carcinoma, prognosis is also poor. The overall five-year survival for patients with SCLC is about 5%. Patients with extensive-stage SCLC have an average five-year survival rate of less than 1%. The median survival time for limited-stage disease is 20 months, with a five-year survival rate of 20%.

Epidemiology

The population segment most likely to develop lung cancer is the over-fifties who also have a history of smoking. Lung cancer is the second most commonly occurring form of cancer in most western countries, and it is the leading cancer-related cause of death. In the US, approximately 213,000 new cases arise each year, and around 160,000 die from it: 114,700 in men and 98,600 in women. Although the rate of men dying from lung cancer is declining in western countries, it is actually increasing for women due to the increased takeup of smoking by this group. Among lifetime non-smokers, men who have never smoked have higher age-standardized lung cancer death rates than women. Of the 80,000 women who are diagnosed with lung cancer in 2006, approximately 70,000 are expected to die from it.

Not all cases of lung cancer are due to smoking, but the role of passive smoking is increasingly being recognized as a risk factor for lung cancer, leading to policy interventions to decrease undesired exposure of non-smokers to others' tobacco smoke. Emissions from automobiles, factories and power plants also pose potential risks.

Eastern Europe has the highest lung cancer mortality among men, while northern Europe and the USA have the highest mortality among women. Lung cancer incidence is less common in developing countries.

History

Lung cancer was extremely rare prior to the advent of cigarette smoking. In 1878, malignant lung tumors made up only 1% of all cancers seen at autopsy; this had risen to 10–15% by the early 1900s. Case reports in the medical literature numbered only 374 worldwide in 1912. A review of autopsies showed that that the incidence of lung cancer had increased from 0.3% in 1852 to 5.66% in 1952.

Silver has been mined in the Ore Mountains near Schneeberg, Saxony since 1470. However these mines are rich in uranium with accompanying radium and radon gas. Miners developed a disproportionate amount of lung disease, eventually recognized as lung cancer in the 1870s. An estimated 75% of former miners died from lung cancer. Despite this discovery, mining continued into the 1950s due to the USSR's need for uranium.

In Nazi Germany, scientists recognized the link between smoking and lung cancer. This led to an aggressive anti-smoking campaign. The British Doctors Study, published in the 1950s, was the first solid epidemiological evidence of the link between lung cancer and smoking.

References

1. WHO (Feb 2006). "Cancer". World Health Organization. Retrieved 2007-06-25.
2. WHO (2004). "Deaths by cause, sex and mortality stratum" (PDF). World Health Organization. Retrieved 2007-06-01.
3. "Lung Cancer Facts (Women)". National Lung Cancer Partnership. 2006. Retrieved 2007-05-26. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
4. ^ Samet, JM (May 1988). "Cigarette smoking and lung cancer in New Mexico". American Review of Respiratory Disease. 137 (5): 1110–1113. PMID 3264122. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
5. Gorlova, OY (Jul 2007). "Aggregation of cancer among relatives of never-smoking lung cancer patients". International Journal of Cancer. 121 (1): 111–118. PMID 17304511. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
6. Hackshaw, AK (Oct 1997). "The accumulated evidence on lung cancer and environmental tobacco smoke". British Medical Journal. 315 (7114): 980–988. PMID 9365295. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
7. ^ Catelinois, O (May 2006). "Lung Cancer Attributable to Indoor Radon Exposure in France: Impact of the Risk Models and Uncertainty Analysis". Environmental Health Perspectives. 114 (9). National Institute of Environmental Health Science: 1361–1366. doi:10.1289/ehp.9070. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
8. ^ Kabir, Z (2007). "Lung cancer and urban air-pollution in dublin: a temporal association?". Irish Medical Journal. 100 (2): 367–369. PMID 17432813. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
9. Coyle, YM (2006). "An ecological study of the association of metal air pollutants with lung cancer incidence in Texas". Journal of Thoracic Oncology. 1 (7): 654–661. PMID 17409932. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
10. ^ Chiu, HF (Dec 2006). "Outdoor air pollution and female lung cancer in Taiwan". Inhal Toxicol. 18 (13): 1025–1031. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
11. ^ Minna, John D (2005). Harrison's Principle's of Internal Medicine. p. 506. doi:10.1036/0071402357. {{cite book}}: Cite has empty unknown parameter: |coauthors= (help)
12. ^ Vaporciyan, Ara A (2000). Cancer Medicine. p. 1227. ISBN 1-55009-113-1. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
13. Subramanian, J (Feb 2007). "Lung cancer in never smokers: a review". Journal of Clinical Oncology. 25 (5). American Society of Clinical Oncology: 561–570. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
14. ^ Raz, DJ (Mar 2006). "Bronchioloalveolar carcinoma: a review". Clinical Lung Cancer. 7 (5). Cancer Information Group: 313–322. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
15. Veronesi G (2006). "Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases". Lung Cancer. 53 (1): 111–115. doi:10.1016/j.lungcan.2006.03.007. PMID 16697073. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
16. Morandi, U (2006). "Bronchial typical carcinoid tumors". Seminars in Thoracic and Cardiovascular Surgery. 18 (3): 191–198. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
17. Moran, CA (Mar 1994). "Primary adenoid cystic carcinoma of the lung. A clinicopathologic and immunohistochemical study of 16 cases". Cancer. 73 (5): 1390–1397. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
18. Sánchez-Mora, N (Jan 2007). "Mucoepidermoid tumors of the bronchus. Ultrastructural and immunohistochemical study". Histology and Histopathology. 22 (1): 9–13. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
19. Mountain, Clifton F. A Handbook for Staging, Imaging, and Lymph Node Classification. Charles P Young Company. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
20. Collins, LG (Jan 2007). "Lung cancer: diagnosis and management". American Family Physician. 75 (1). American Academy of Family Physicians: 56–63. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
21. ^ "Lung Cancer Clinical Presentation". Lung Cancer. Armenian Medical Network. Retrieved 2007-05-22. {{cite web}}: Text "Eric B. Haura, Susan A. Blackwell, and Jeffrey Crawford" ignored (help)
22. Villeneuve, PJ (Nov 1994). "Lifetime probability of developing lung cancer, by smoking status, Canada". Canadian Journal of Public Health. 85 (6): 385–388. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
23. Hecht, S (Oct 2003). "Tobacco carcinogens, their biomarkers and tobacco-induced cancer". Nature Reviews. Cancer. 3 (10). Nature Publishing Group: 733–744. doi:10.1038/nrc1190. {{cite journal}}: Cite has empty unknown parameter: |coauthors= (help)
24. Peto R, R (1994). Mortality from smoking in developed countries 1950–2000: Indirect estimates from National Vital Statistics. Oxford: Oxford University Press. ISBN 0-19-262535-7. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
25. Nordquist, LT (Aug 2004). "Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung". Chest. 126 (2): 347–351. Retrieved 2007-07-27. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
26. Tammemagi, CM (Jan 2004). "Smoking and lung cancer survival: the role of comorbidity and treatment". Chest. 125 (1): 27–37. Retrieved 2007-07-30. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
27. CDC (Dec 1986). "The health consequences of involuntary smoking". CDC. Retrieved 2007-08-01. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
28. US Department of Health and Human Services., The health consequences of involuntary smoking: report of the Surgeon General (DHHS Pub No (PHS) 87–8398), DHHS, Washington, DC (1986). PMID 3097495
29. National Research Council., Environmental tobacco smoke: measuring exposures and assessing health effects, NRC, Washington, DC (1986).
30. US Environmental Protection Agency., Respiratory health effects of passive smoking: lung cancer and other disorders, EPA, Washington, DC (1992).
31. California Environmental Protection Agency., Health effects of exposure to environmental tobacco smoke, California EPA, Sacramento (1997). PMID 9583639.
32. Centers for Disease Control and Prevention (CDC). State-specific prevalence of current cigarette smoking among adults, and policies and attitudes about secondhand smoke--United States, 2000. MMWR Morb Mortal Wkly Rep. 2001 Dec 14;50(49):1101-6. PMID 11794619
33. Alberg, AJ (Jan 2003). "Epidemiology of lung cancer". Chest. 123 (S1): 21S–49S. Retrieved 2007-08-01. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
34. In: P Boffetta, A Agudo and W Ahrens et al., Editors, Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe, J Natl Cancer Inst 90 (1998), pp. 1440–1450.
35. "Report of the Scientific Committee on Tobacco and Health". Department of Health. Mar 1998. Retrieved 2007-07-09. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
36. Hackshaw AK. Lung cancer and passive smoking. Stat Methods Med Res. 1998 Jun;7(2):119-36. PMID 9654638
37. National Health and Medical Research Council., The health effects of passive smoking, Australian Government Publishing Service, Canberra (1997).
38. Ong, EK (Apr 2000). "Tobacco industry efforts subverting International Agency for Research on Cancer's second-hand smoke study". Lancet. 355 (9211): 1253–1259. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
39. Philip Morris USA. "Philip Morris USA Document Site". Retrieved 2007-08-01. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
40. Schick, S (Dec 2005). "Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke". Tobacco Control. 14 (6): 396–404. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
41. Hammond, E.C. "Asbestos exposure, cigarette smoking and death rates". Ann N Y Acad Sci (330). 1979: 473. PMID 294198. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
42. "Radiation information: radon". Environmental Protection Agency. Oct 2006. Retrieved 2007-05-25. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
43. Field, RW (Jun 2000). "Residential radon gas exposure and lung cancer: the Iowa Radon Lung Cancer Study". American Journal of Epidemiology. 151 (11). Oxford Journals: 1091–1102. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
44. "Iowa Radon Lung Cancer Study". Environmental Protection Agency. Jun 2000. Retrieved 2007-05-25. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
45. Leroux, C (Mar–Apr 2007). "Jaagsiekte Sheep Retrovirus (JSRV): from virus to lung cancer in sheep". Veterinary Research. 38 (2): 211–228. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: date format (link)
46. Palmarini, M (Nov 2001). "Retrovirus-induced ovine pulmonary adenocarcinoma, an animal model for lung cancer". Journal of the National Cancer Institute. 93 (21). Oxford University Press: 1603–1614. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
47. Cheng, YW (Apr 2001). "The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women". Cancer Research. 61 (7). American Association for Cancer Research: 2799–2803. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
48. Zheng, H (May 2007). "Oncogenic role of JC virus in lung cancer". Journal of Pathology. 212 (3): 306–315. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
49. Giuliani, L (Mar 2007). "Detection of oncogenic viruses (SV40, BKV, JCV, HCMV, HPV) and p53 codon 72 polymorphism in lung carcinoma". Lung Cancer. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
50. Fong, KM (Oct 2003). "Lung cancer. 9: Molecular biology of lung cancer: clinical implications". Thorax. 58 (10). BMJ Publishing Group Ltd.: 892–900. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
51. Salgia, R (Mar 1998). "Molecular abnormalities in lung cancer". Journal of Clinical Oncology. 16 (3): 1207–1217. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
52. Aviel-Ronen, S (Jul 2006). "K-ras mutations in non-small-cell lung carcinoma: a review". Clinical Lung Cancer. 8 (1). Cancer Information Group: 30–38. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
53. Devereux, TR (Mar 1996). "Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors". Chest. 109 (Suppl. 3). American College of Chest Physicians: 14S–19S. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
54. Engels, EA (Jul 2007). "Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer". Cancer Research. 67 (13). American Association for Cancer Research: 6520–6527. doi:10.1158/0008-5472.CAN-07-0370. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
55. Wenzlaff, AS (Dec 2005). "CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study". Carcinogenesis. 26 (12). Oxford University Press: 2207–2212. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
56. Yin, J (May 2007). "The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population". Lung Cancer. 56 (2): 153–160. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
57. Vineis, P (Feb 2007). "Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study". Environmental Health. 6: 7. doi:10.1186/1476-069X-6-7. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
58. Gohagan, JK (Jan 2005). "Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer". Lung Cancer. 47 (1): 9–15. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
59. H. Gilbert Welch, Steven Woloshin, and Lisa M. Schwartz, Essay: How Two Studies on Cancer Screening Led to Two Results, New York Times, March 13, 2007
60. El-Sherif, A (Aug 2006). "Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis". Annals of Thoracic Surgery. 82 (2): 408–415. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
61. Fernando, HC (Feb 2005). "Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer". Journal of Thoracic and Cardiovascular Surgery. 129 (2): 261–267. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
62. Clegg, A (Jan 2002). "Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review". Thorax. 57 (1). BMJ Publishing Group Ltd: 20–28. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
63. Murray, N (Mar 2006). "A review of first-line treatment for small-cell lung cancer". Journal of Thoracic Oncology. 1 (3): 270–278. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
64. Azim, HA (Mar 2007). "Treatment options for relapsed small-cell lung cancer". Anticancer drugs. 18 (3): 255–261. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
65. MacCallum, C (Jul 2006). "Second-line treatment of small-cell lung cancer". Current Oncology Reports. 8 (4): 258–264. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
66. Winton, T (Jun 2005). "Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer". New England Journal of Medicine. 352 (25). Massachusetts Medical Society: 2589–2597. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
67. Douillard, JY (Sep 2006). "Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ): a randomised controlled trial". Lancet Oncology. 7 (9): 719–727. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
68. Tsuboi, M (2007). "The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer" (PDF). Ann Thorac Cardiovasc Surg. 13 (2): 73–77. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
69. Horn, L (May 2007). "The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer". Journal of Thoracic Oncology. 2 (5): 377–383. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
70. Wakelee, HA (Jul 2006). "Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial". Clinical Lung Cancer. 8 (1). Cancer Information Group: 18–21. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
71. Clinical Evidence: concise, BMJ Publishing Group, London. 2006. ISBN 1-90554501206 ISSN 1465-9225
72. Wagner, H (Jan 1998). "Radiation therapy in the management of limited small cell lung cancer: when, where, and how much?". Chest. 113 (Suppl. 1). American College of Chest Physicians: 92S–100S. {{cite journal}}: Cite has empty unknown parameter: |coauthors= (help)
73. Ng, M (Jun 2007). "Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience". Journal of Thoracic Oncology. 2 (6). International Association for the Study of Lung Cancer: 506–513. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
74. Simon, CJ (Apr 2007). "Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients". Radiology. 243 (1): 268–275. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
75. Feld, R (May 2006). "Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review". Journal of Thoracic Oncology. 1 (4). International Association for the Study of Lung Cancer: 367–376. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
76. Bencardino, K (Mar 2007). "Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues". Internal and Emergency Medicine. 2 (1): 3–12. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
77. Lee, JM (Apr 2007). "Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC". Future Oncology. 2 (2): 149–153. PMID 17381414. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
78. Whitehead, Clark M (May 2003). "Exisulind-induced Apoptosis in a Non-Small Cell Lung Cancer Orthotopic Lung Tumor Model Augments Docetaxel Treatment and Contributes to Increased Survival". Molecular Cancer Therapeutics. 2. American Association for Cancer Research: 479–488. PMID 12748310. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
79. Scagliotti, G (Jun 2006). "Proteasome inhibitors in lung cancer". Critical Reviews in Oncology/Haematology. 58 (3): 177–189. PMID 16427303.
80. Dragnev, KH (Mar 2007). "A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer". Clinical Cancer Research. 13 (6). American Association for Cancer Research: 1794–1800. PMID 17363535. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
81. Albright, C (Jul 2007). "Vaccine therapy in non-small cell lung cancer". Current Oncology Reports. 9 (4): 241–246. PMID 17588347. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
82. Edelman, MJ (Sep 2006). "Novel cytotoxic agents for non-small cell lung cancer". Journal of Thoracic Oncology. 1 (7): 752–755. PMID 17409954.
83. Danesi, R (May 2007). "The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer". Journal of Thoracic Oncology. 2 (5 Suppl.): S27–S30. PMID 17457227. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
84. Blackhall, FH (Mar 2007). "Small cell lung cancer and targeted therapies". Current Opinion in Oncology. 19 (2): 103–108. PMID 17272981. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
85. Mountain, Clifton F (1997). "Revisions in the international system for staging lung cancer" (PDF). Chest. 111. American College of Chest Physicians: 1710–1717. PMID 9187198. Retrieved 2007-08-09.
86. ^ "Lung Carcinoma: Tumors of the Lungs". Merck Manual Professional Edition, Online edition. Retrieved March 19. {{cite web}}: Check date values in: |accessdate= (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
87. Vidaver, Regina (July 2007). "Lung cancer in the United States: Facts". National Lung Cancer Partnership. Retrieved 2007-07-10.
88. "New survey finds most women don't know much about lung cancer even though it's the leading cancer killer of women in the U.S." (Press release). National Lung Cancer Partnership. June 02, 2006. Retrieved 2007-08-10. {{cite press release}}: Check date values in: |date= (help)
89. Parent, ME (Jan 2007). "Exposure to diesel and gasoline engine emissions and the risk of lung cancer". American Journal of Epidemiology. 165 (1): 53–62. PMID 17062632. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
90. "Gender in lung cancer and smoking research" (PDF). World Health Organization. 2004. Retrieved 2007-05-26.
91. Witschi, H (Nov 2001). "A short history of lung cancer". Toxicological Sciences. 64 (1): 4–6. PMID 11606795.
92. Adler I. Primary malignant growths of the lungs and bronchi. New York: Longmans, Green, and Company; 1912., cited in Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9. PMID 15961694
93. Grannis, FW. "History of cigarette smoking and lung cancer". smokinglungs.com. Retrieved 2007-08-06.
94. Greaves, Mel (2000). Cancer: the Evolutionary Legacy. Oxford University Press. pp. 196–197. ISBN 0-19-262835-6.
95. Proctor, R (2000). The Nazi War on Cancer. Princeton University Press. pp. 173–246. ISBN 0-691-00196-0.
96. Doll, R (Nov 1956). "Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors". British Medical Journal. 2 (5001): 1071–1081. PMID 13364389. {{cite journal}}: Cite has empty unknown parameter: |1= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

External links

• Template:Dmoz
• Tobacco Smoke and Involuntary Smoking, Summary of Data Reported and Evaluation 2004 by the IARC
• Lung Cancer Articles & Information Stop Smoking Articles & Information at National Institutes of Health

• Pulmonology
• Types of cancer
• Lung cancer